Investorideas.com - Nation's Largest Marijuana Policy Reform Group Releases Report on Cannabis Vaping Regulations
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Wednesday, October 2, 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Interview with Todd Morrow, President of HempMeds, subsidiary of Medical Marijuana Inc. (OTC: $MJNA)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Interview with Todd Morrow, President of HempMeds, subsidiary of Medical Marijuana Inc. (OTC: $MJNA)
Delta, Kelowna, BC –October 2, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/10021Interview-ToddMorrow-OTCMJNA.asp
In today’s podcast I interview Todd Morrow, President of HempMeds, a subsidiary of Medical Marijuana Inc. (OTC:MJNA), where we discussed the recent developments for HempMeds as well as the CBD space in general.
For those unfamiliar with HempMeds story Todd elaborated, “HempMeds was the first company to ever bring hemp based CBD oil products to market in the U.S. back in 2012. The company was also the first ever company to receive the historic federal government import approval for CBD products from Argentina, Brazil, Mexico and Paraguay as well as the first to have product listed in the prescribers digital reference. We are the only hemp-CBD product, our RSHO (Real Scientific Hemp Oil) Gold is the only product to be listed in the physicians reference.”
As Todd and HempMeds have been involved in the CBD space since its inception in the U.S. market, Todd discussed the changes he and his company have noticed take place over the last few years. “We’ve been sourcing industrial hemp from the Netherlands from the very beginning which has given us the opportunity to trade across state lines since the beginning. The landscape is very interesting out there and very confusing for consumers. Many consumers have heard of CBD but they don’t know what to look for in products. In the beginning there was just a few CBD companies and a few CBD options
and now the market is flooded with thousands of CBD companies brining CBD products to market. Unfortunately, we’ve got a lot of folks out there that are making claims on their package that they can’t substantiate or saying that there’s one thing in the bottle when there’s really something else. This creates a wild west out there and is very confusing for consumers. We really believe that a large portion of our responsibility is education. We’ve put a lot of time,energy and effort into educating consumers not only on our product but also on the options available in the marketplace and what consumers should be looking for when they’re looking to buy CBD product. What sets us apart from a lot of the other players is our full spectrum oils. All of our products, under the RSHO brand, are premium industrial hemp/CBD oil.”
Discussing how the education component of the industry, an element most companies within either the hemp/CBD or cannabis/THC industries consider paramount, may change with FDA regulations coming into the market, Todd explained, “I do believe that once the FDA gets involved, a lot of those concerns will fall to the wayside. I think there’s going to be quite a tremendous shake out. There will be standardization around what’s allowed and what’s not, what is required on the label and all the certifications from soil all the way to a finished good, will be required, or should be required. With the FDA involvement, this should take a lot of the owness away from the consumer, but you still always want to make sure your due diligence in your research.”
Medical Marijuana, Inc. through their subsidiary HempMeds recently announced that the Company has reached a one-year milestone for long-term stability testing on its flagship THC-free cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™). The stability study was conducted in strict compliance with FDA/ICH guidelines (Q1A-R2).
“Our consumers and retail partners deserve the transparency and security of understanding how stable and dependable our products are throughout numerous climatic conditions and transportation scenarios,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This long-term study illustrates our deep commitment to creating and distributing safe, high-quality products to consumers worldwide and we aim to continue conducting similar studies in the future with our other industry leading CBD products.”
The stability study tested multiple samples of RSHO-X™ while being exposed to various environmental conditions that may be experienced in various locations throughout the world. The samples, which were tested for appearance, odor, specific gravity, viscosity, package compatibility, and complete microbial characteristics, showcased that the product is stable at the end of a one-year time period and has identical CBD concentrations to what existed at the beginning of the study.
The study was outsourced to one of the most qualified cGLP/cGMP compliant Contract Research Organizations (CROs) with attained ISO 17025 accreditation and certification.
It was performed using fully validated, proprietary analytical UPLC-PDA and LC-MS/MS methods reflecting the specificity and selectivity toward RSHO-X™, including data elements and parameters such as accuracy, precision, repeatability, ruggedness, system suitability, linearity, specificity, dilution integrity, and dynamic range.
The test results showed no change (no more than 5%) in the CBD content and other specifications were observed and the container closure system was faultless at both long-term and accelerated test conditions.
The positive 12-month, long-term stability test results suggest that RSHO-X™ is a stable formulation. The stability testing will be continued for up to 24 months and a corresponding shelf-life of 24 months is anticipated.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Tuesday, October 1, 2019
Investorideas.com - Cannabis Stock News: GreenStar Biosciences' (CSE: GSTR) Cowlitz Generates US$11.8M in First Seven Months of 2019
Investorideas.com - Cannabis Stock News: GreenStar Biosciences' (CSE: GSTR) Cowlitz Generates US$11.8M in First Seven Months of 2019
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Interview with Robert Galarza, Director and CEO of TruTrace Technologies (CSE: $TTT.C) (OTC: $TTTSF)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Interview with Robert Galarza, Director and CEO of TruTrace Technologies (CSE: $TTT.C) (OTC: $TTTSF)
Delta, Kelowna, BC –October 1, 2019 (Investorideas.com Newswire)
(Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/10011Interview-RobertGalarza-CSETTT.asp
In today’s podcast I interview Robert Galarza, Director and CEO of TruTrace Technologies Inc. (CSE: TTT) (OTC: TTTSF), where we discussed the company’s pilot program with Shoppers Drug mart and future of the cannabis industry.
TruTrae’s “Pilot Program” recently completed Phase 1 and is moving into Phase 2, where the company is beginning to gain real traction with industry names such as it’s recent partnership with Deloitte as well as having one of the larger LP’s Aphria join the pilot progam as well.
Robert commented on the completion of Phase 1 and moving into Phase 2, saying, “In our years in the industry, we really started to understand that the most important data point on the product, in terms of medical efficacy, or trust, or product integrity was the identification of the product. You can’t really track/trace anything else unless you really know what it is. Genetic and chemistry testing, associated with these products really held the key. There’s a lot of great chemistry out there, but genetics is the one thing that can’t change on a product line in a clone based propagation, if you have a consistent and visible supply chain. In this world of buying and selling inventory from different LP’s, I think everyone is wanting a really strong level set on exactly what this product is.”
Robert continued, “It’s a really amazing thing when you get introduced to the largest pharmacy in Canada (Shoppers Drugmart). They’re the Walgreens and CVS combined in Canada. What blew us away was their knowledge of cannabis. They had been in this industry for six years quietly behind the scenes, and they understood all of it. They understood the black market, the grey market, the MMAR, the MNPR, the designated cultivators, the growers, everything associated with this industry they understood at a deep level, and they were running into a consistent challenge, which was: as a medical practitioner there’s no romance about cannabis. Everything is about facts and medicine and research and information. They were running into the same problem that we saw which was there’s no integrity and standardization behind these products. Our platform at its core really resonated with them. Phase 1 was initial stage implementation of the core platform into the Shoppers ecosystem and into an initial LP WeedMD, who was out first client, and getting that through line to show that it could all work. Phase 2 has been about onboarding the other suppliers and having Deloitte to come in and help us manage the scope of the project. Even with seven large licensed producers, it’s a lot of moving parts. What’s been amazing is once we’ve built the system where we’ve validated that product, and we’ve got the security and visibility at the core of our information, it’s amazing who wants access to that information. That’s where the physician networks and hospital networks have popped up.”
When asked about the different approach TruTrace has taken in the U.S. market versus the Canadian market Robert commented, “In the U.S. we’ve taken a little bit of a different approach. Because of the federal landscape here, we’re kind of planting the seed as we don’t know exactly what the future is going to hold for the United States. Those of us that have lived here and been involved in the marketplace are of the belief that we will see medical legalization occur in the next couple of years. What that allows, is it allows patients to access safe medicine in all jurisdictions across the country and it allows the FDA to come in and implement the kind of standards and practices around testing so people are getting safe product. Safe product is the key. You can’t just open the thing up to open market capitalism.”
Robert continued to talk about the potential of TruTrace moving forward and the possibilities for collaborations in the future as well as trends being noticed in the cannabis market.
If you enjoyed this podcast we recommend listening to our interview with Andrew Muroff from StrainPrint Technologies here.
https://www.investorideas.com/news/2019/cannabis-potcasts/09201Interview-StrainprintTechnologies.asp
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Subscribe to:
Posts (Atom)